Print Page     Close Window     

SEC Filings

10-Q
BIOTIME INC filed this Form 10-Q on 08/09/2017
Entire Document
 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
 
SCHEDULE A
 
Share Transfer Deed
 
Schedule A
 

Share Transfer Deed
 
The undersigned, HBL-Hadasit Bio-Holdings Ltd. (the “Transferor”), hereby transfers to BioTime, Inc. (the “Transferee”), for consideration received, the sufficiency of which is hereby acknowledged, all of the rights, title and interests in 96,025 Ordinary Shares, par value NIS 0.01 each of Cell Cure Neurosciences ltd. (“Cell Cure”) to hold unto the Transferee and the successors and assigns of the Transferee, all upon the terms and conditions pursuant to the Articles of Association of Cell Cure, as shall be in effect from time to time., and the Transferree does hereby agree to accept and hold such shares subject to the above terms and conditions.
 
BioTime, Inc.
 
HBL-Hadasit Bio-Holdings Ltd.
 
       
 
 
 
 
Name: Aditya Mohanty
Name: Baruch Halpert
Title: Co-Chief Executive Officer
 
Title: Chairman
 
 
   
 
   
Name: Yoram Azulai
   
Title: CFO, acting CEO
       
 
 
 
Witness to the signature
 
Witness to the signature
of the Transferee
 
of the Transferor
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
 
13

© Copyright BioTime, Inc.